FDA WARNING_LETTER - Ready Med - May 01, 2026

On June 8, 2026, the FDA issued a warning letter to Ready Med, based in Clearwater, Florida, following a May 2026 review of the company"s website. The regulatory agency identified significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act), specifically regarding the sale and promotion of compounded semaglutide and tirzepatide products. The FDA concluded that these products are misbranded under sections 502(a) and 502(bb) due to false or misleading representations. Key violations include labeling that incorrectly suggests Ready Med is the actual manufacturer of the drugs and advertising claims that equate the compounded products to FDA-approved medications like Ozempic and Mounjaro. These claims falsely imply that the compounded versions have undergone the same rigorous safety and efficacy evaluations as their brand-name counterparts. Additionally, the company misleadingly described its sourcing facilities as "FDA licensed" or "FDA approved," which are not designations the agency grants to compounding pharmacies. To achieve compliance, Ready Med must submit a written response within 15 business days outlining its corrective actions. Required steps include identifying the actual producers of the medications, providing representative product labels, and removing all misleading claims from its digital platforms. Failure to rectify these issues may lead to legal consequences such as product seizures or court-ordered injunctions.